An ongoing dialogue on HIV/AIDS, infectious diseases,
October 23rd, 2011
TB, Timing of Antiretroviral Therapy, and Being a Lumper Rather Than a Splitter
Three key papers on timing of ART in patients with TB have just been published in the New England Journal of Medicine. Fortunately, Carlos Del Rio has done a bang-up job summarizing them in Journal Watch AIDS Clinical Care. And if you’re wondering how we got our title for Carlos’ piece, here’s an e-mail between our Executive Editor to me […]
October 19th, 2011
Going, Going, Gone … HIV Treatment Failure Is Disappearing in People Who Take Their Meds
World Series time, hence the baseball reference in the title. (Doesn’t take much.) But over in Lancet Infectious Diseases — which has turned out to be a terrific journal, by the way — there’s a study reminding us that advances in HIV treatment in the late 2000s were truly spectacular. The goal of the paper was to track […]
October 4th, 2011
Hormonal Contraception MAY Increase Risk of HIV
From the pages of Lancet Infectious Diseases, a study from Africa: We aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners … Among 1314 couples in which the HIV-1-seronegative partner was female, rates of HIV-1 acquisition were 6·61 per […]
October 4th, 2011
Spanish HIV Vaccine Story Gets Lots of Attention — Here’s Why
If you’re looking for a good way to pass the time while running errands, traveling, or walking to work, I highly recommend the Freakonomics podcasts, which have taught me all sorts of interesting things. Such as the fact that suicide is more common than murder in the USA, but gets way less attention. And how a […]
October 3rd, 2011
CASCADE: When to Start, (Yet) Another Take
As we await the enrollment, analysis, and results of the START study — which is randomizing patients with CD4>500 to start HIV therapy vs waiting until the CD4 falls to 350 — much of the research on “when to start” ART in patients with high CD4’s comes from observational studies. Several have already been published […]
September 24th, 2011
Warning: Viral Replication is Hazardous to Your Health
When studies evaluate the prognostic importance of measuring HIV viral load, they generally do so by assessing a single measurement rather than values obtained longitudinally. One obvious limitation of this approach is that baseline VL poorly predicts outcome after ART initiation — a finding in stark contrast to the original description of VL from the […]
September 22nd, 2011
Common Sense on HIV Testing
There’s an editorial in today’s Boston Globe that concisely (188 words) describes the problems with both the current and proposed HIV testing laws in Massachusetts. I’ve not been shy about the fact that I agree with every word of this piece. And though I strongly recommend reading the whole editorial — it’s very well written — if you […]
September 4th, 2011
“Novel” Approaches to Initial HIV Therapy: Part II
Two studies were just published on alternative strategies for initial HIV therapy. I’ve already reviewed the first one here. The second paper is a single-arm (n=112) study of darunavir/r (once daily) plus raltegravir, the latest riff on the “NRTI sparing” approach. As I mentioned when I first covered this study, the high rate of virologic failure — […]
September 3rd, 2011
“Novel” Approaches to Initial HIV Therapy: Part I
It’s been several years since the “preferred” or “recommended” initial regimens for HIV treatment have been consolidated into one of the following four: TDF/FTC + efavirenz TDF/FTC + atazanavir/r TDF/FTC + darunavir/r TDF/FTC + raltegravir Any room for improvement in this “TDF/FTC + key third drug” approach? With the recent approval of TDF/FTC/rilpivirine, certainly this will […]
August 19th, 2011
A Reason To Continue Restrictive HIV Testing Laws? Not Really …
The pending HIV legislation is much on my mind these days, for reasons I outlined here. Bottom line is that I don’t think it’s good for patient care, and we’re missing a real opportunity to make things better here in the Bay State. But yesterday I heard a perspective on the bill I hadn’t considered, and […]
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
NEJM Journal Watch — Recent Infectious Disease Articles- Is Cardiovascular Risk Sustained After SARS-CoV-2 Infection?
- Which Hepatitis B Vaccine Provides the Longest-Lasting Protection in People with HIV?
- Lenacapavir for HIV Preexposure Prophylaxis: Guidance from the IAS–USA
- Is All-Oral Treatment an Option for Whipple's Disease?
- Two Doses of Recombinant Zoster Vaccine Worked Well in People 50 and Older